Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing the Efficacy, Safety and Dose-response of Quinagolide Extended-release Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate to Severe Endometriosis-related Pain

NCT03692403 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT03692403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03692403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing the Efficacy, Safety and Dose-response of Quinagolide Extended-release Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate to Severe Endometriosis-related Pain
Lead sponsor
Ferring Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 26, 2018
Completion date
February 14, 2022
Enrollment
22 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis-related pain